Your browser is no longer supported. Please, upgrade your browser.
CRTX Cortexyme, Inc. daily Stock Chart
Cortexyme, Inc.
Index- P/E- EPS (ttm)-1.67 Insider Own51.21% Shs Outstand25.23M Perf Week20.07%
Market Cap1.48B Forward P/E- EPS next Y-1.65 Insider Trans0.00% Shs Float13.11M Perf Month38.83%
Income-27.10M PEG- EPS next Q-0.40 Inst Own31.40% Short Float11.81% Perf Quarter153.09%
Sales- P/S- EPS this Y-2.00% Inst Trans0.88% Short Ratio8.83 Perf Half Y39.95%
Book/sh4.74 P/B12.37 EPS next Y5.20% ROA- Target Price66.40 Perf Year-
Cash/sh4.77 P/C12.29 EPS next 5Y- ROE- 52W Range19.35 - 72.94 Perf YTD4.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-19.61% Beta-
Dividend %- Quick Ratio20.30 Sales past 5Y- Gross Margin- 52W Low203.05% ATR6.16
Employees19 Current Ratio20.30 Sales Q/Q- Oper. Margin- RSI (14)62.23 Volatility12.77% 14.00%
OptionableNo Debt/Eq0.00 EPS Q/Q-207.40% Profit Margin- Rel Volume0.66 Prev Close62.62
ShortableYes LT Debt/Eq0.00 EarningsFeb 11 BMO Payout- Avg Volume175.50K Price58.64
Recom2.40 SMA209.19% SMA5052.80% SMA20085.74% Volume115,882 Change-6.36%
Jun-03-19Initiated JMP Securities Mkt Outperform $53
Jun-03-19Initiated Credit Suisse Underperform $14
Jun-03-19Initiated Canaccord Genuity Buy $42
Jun-03-19Initiated BofA/Merrill Neutral $28
Jan-13-20 08:00AM  Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimers Disease Business Wire
Jan-08-20 04:05PM  Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020 Business Wire
Jan-05-20 08:14AM  Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation Simply Wall St.
Jan-03-20 10:15AM  Last year's Bay Area IPO performances show why it pays to be an insider American City Business Journals -8.92%
Dec-22-19 06:38PM  Hedge Funds Have Never Been This Bullish On Cortexyme, Inc. (CRTX) Insider Monkey
Dec-13-19 11:16AM  The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber Zacks +11.00%
Dec-11-19 06:32PM  5 Hottest IPOs of 2019 Zacks
Dec-09-19 08:44AM  Fiverr Languishes Below IPO Price as First Chance to Sell Nears Bloomberg +12.72%
Dec-07-19 01:00PM  Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimers Disease Business Wire
Dec-02-19 01:56PM  Biogen's shares drop on critical view of Alzheimer's data MarketWatch +8.00%
Nov-26-19 04:05PM  Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019 Business Wire
Nov-12-19 04:05PM  Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-08-19 10:34AM  The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme Zacks +5.25%
Nov-07-19 08:18AM  4 Best-Performing IPOs So Far in 2019 Zacks +7.99%
Nov-01-19 08:00AM  Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimers Disease 2019 Business Wire
Oct-09-19 09:14AM  Top Ranked Momentum Stocks to Buy for October 9th Zacks
Oct-07-19 09:36AM  Did Cortexyme, Inc. (NASDAQ:CRTX) Insiders Buy Up More Shares? Simply Wall St.
Sep-26-19 08:00AM  Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial Business Wire
Sep-23-19 10:54AM  Top Ranked Momentum Stocks to Buy for September 23rd Zacks
Aug-08-19 11:45AM  What Percentage Of Cortexyme, Inc. (NASDAQ:CRTX) Shares Do Insiders Own? Simply Wall St. -9.63%
Jul-31-19 04:05PM  Cortexyme to Present at the Canaccord Genuity Growth Conference on August 7th Business Wire
Jul-17-19 11:00AM  Cortexymes Approach to Addressing a Key Underlying Cause of Alzheimers Detailed at Alzheimers Association International Conference 2019 Business Wire
Jul-10-19 08:00AM  Cortexyme Announces Upcoming Data Presentations at the Alzheimers Association International Conference 2019 Business Wire
Jul-05-19 10:05AM  These Bay Area companies are part of an uptick in women-led IPOs American City Business Journals -6.21%
Jul-01-19 02:08PM  Here are big Bay Area winners, losers from busy first half of IPOs American City Business Journals +6.52%
Jun-26-19 12:31PM  Cortexyme's unique approach to Alzheimer's research Yahoo Finance Video
Jun-19-19 08:00AM  Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts Business Wire
Jun-10-19 08:00AM  Cortexyme to Present at National Academies Forum on Tuesday, June 11, 2019 Business Wire
May-08-19 07:22PM  Cortexyme, Inc. Announces Pricing of Initial Public Offering Business Wire
May-04-19 05:25PM  IPO Outlook For The Week: Uber (And 11 Others) Benzinga
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.